Public Policy
RSSAs the global biologics unit for AstraZeneca, MedImmune focuses specifically on public policy issues that impact large-molecule, biologic therapies and vaccines. MedImmune also aligns its positions with and helps develop AstraZeneca positions that span the broader biopharmaceutical environment.
We strive to make our relevant positions clear and transparent, facilitate an atmosphere of constructive dialogue on key issues with many involved stakeholders, and achieve our business objectives responsibly. Please click on the links below to learn more about our views and policy positions.
Click to view AstraZeneca’s U.S.-based public policy positions, “AZ on the Issues”. Click to view AstraZeneca’s global public policy positions on the “Responsibility Section”.
Access to Care
Viewing 1 - 2 of 2RSV: RESPIRATORY SYNCYTIAL VIRUS
A COMMON AND POTENTIALLY SERIOUS VIRUS MAY ENDANGER PREEMIES IN THE UNITED STATES RSV is the Leading Cause of Hospitalization in Infants Less Than 1 Year of Age1 Respiratory s... » read more
POSITION ON STATE MEDICAID DRUG REIMBURSEMENT FOR BIOLOGICS
Recognizing the unique nature of biologics, MedImmune supports appropriate Medicaid reimbursement for biologics, including for care management services, to help ensure patient... » read more
Biosimilars
Viewing 1 - 1 of 1POSITION ON BIOSIMILARS
MedImmune supports the establishment of a regulatory pathway for the approval of biosimilars in the U.S. that ensures patient safety, product efficacy and continued incentives... » read more
Vaccines
Viewing 1 - 2 of 2POSITION ON SCHOOL-BASED INFLUENZA VACCINATION PROGRAMS
MedImmune supports the implementation of school-based influenza vaccination to help protect school-aged children from seasonal influenza, protect the public health by reducing... » read more
